Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

By: www.fool.com|11/16/2026 22:07:02

Moderna's stock has surged over 600% this year, reaching a market cap close to 90000 million dollars, driven by positive clinical trial results for its cancer vaccine, intismeran, developed in collaboration with Merck. On Aug. 19, phase 3 trial results indicated that intismeran, when combined with Merck's Keytruda, significantly reduced the risk of death and cancer recurrence in melanoma patients. Despite the promising results, the vaccine has not yet received approval, and there are concerns about the stock's inflated valuation. Investors may be overestimating the potential for intismeran to treat multiple cancers, which remains uncertain. Additionally, the production of a personalized cancer vaccine at scale poses operational challenges and costs. The profit-sharing agreement between Moderna and Merck could further limit Moderna's long-term profitability. Given these factors, the current stock price may not be sustainable, and potential investors should exercise caution.

-- Price

--
--
--

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

You may also like

iconiconiconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Program:support@weex.com